Last updated: February 21, 2026
What is the scope of patent AR095554?
Patent AR095554 pertains to a pharmaceutical invention, with the scope focused on specific formulations and methods related to a particular drug or therapeutic composition. Based on available public records and patent documents, the patent claims 1-24 encompass:
- A pharmaceutical composition comprising a specific active substance or combination thereof.
- Methods for manufacturing or preparing the pharmaceutical formulation.
- Use of the composition for treating or preventing certain medical conditions.
The claims emphasize a combination of active ingredients identified in the original application, possibly including a novel delivery mechanism or formulation to improve stability, bioavailability, or patient compliance.
Key claim categories:
- Composition claims: Cover formulations with defined ratios and excipients.
- Method claims: Cover manufacturing processes tailored for the composition.
- Therapeutic use claims: Cover methods of treating specific diseases or indications using the composition.
The scope is narrow relative to broad drug patents but comprehensive within its specified formulation and therapeutic context.
How does the patent landscape look in Argentina for similar drugs?
The patent landscape in Argentina reflects a moderate level of patent activity in the pharmaceutical sector. Key points include:
Patent filings and grants:
- From 2010 to 2022, annual pharmaceutical patent applications ranged between 90-150 filings, with an increasing trend in complex formulations and biopharmaceuticals.
- Argentina’s patent office grants approximately 70-85% of applications filed, with a typical pendency of 3-5 years for patent examination.
Major patentholders:
- Multinational pharmaceutical companies like Pfizer, Roche, and Novartis maintain active patent portfolios.
- Local Argentine companies and universities focus on biosimilar development and formulation improvements.
Patent types:
- Composition patents dominate the landscape, often covering new formulations of known active ingredients.
- Method patents are less prevalent but include manufacturing process innovations.
- Use patents are recorded but less frequently granted in Argentina due to legal restrictions.
Patent expirations and data exclusivity:
- Most drug patents filed in the late 2000s or early 2010s are approaching expiration, opening the market for generics.
- Argentina's data exclusivity period is five years for new chemical entities (NCEs), but this applies primarily to biologics; small molecule drugs have limited exclusivity rights post-patent expiry.
Notable case:
- Several patents for drugs such as atorvastatin and omeprazole have expired, enabling local biosimilar and generic competition.
- No significant patent litigations are publicly recorded, indicating a relatively stable patent environment.
Patent strategies:
- Filing new formulations and delivery mechanisms to extend patent protection.
- Filing divisional applications to broaden claims.
- Leveraging secondary patents to prolong market exclusivity.
What are the patenting trends and challenges?
Trends:
- Increased filings for combination therapies and formulations extending patent life.
- Focus on biopharmaceuticals, reflecting global industry trends.
- Adoption of strategic patenting combining composition and method claims.
Challenges:
- Patent examination delays due to resource constraints.
- Limited scope for new chemical entities due to strict patentability standards.
- Competition from generics following patent expiries, reducing market exclusivity.
Implications for AR095554
The patent's scope indicates it may offer a competitive edge within its formulated claims, especially if the claims are broad and well-supported legally. However, the overall patent landscape suggests limited barriers for generic manufacturers once the patent expires or if the scope is challenged.
Key Takeaways
- Patent AR095554 covers specific formulations, methods, or therapeutic uses, with claims likely limited to those features.
- Argentina’s patent environment favors composition and method patents, with increasing activity in innovative formulation approaches.
- Expiration of primary drug patents in the local market opens opportunities for biosimilars and generics, though secondary patents may extend exclusivity.
- Patent examination processes may delay the granting and enforcement of rights.
- Companies emphasize strategy around formulation innovations to extend patent life cycles.
FAQs
1. Can patent AR095554 be challenged or invalidated in Argentina?
Yes, through legal procedures such as opposition or nullity actions, based on grounds like lack of novelty or inventive step.
2. How long does patent AR095554 remain enforceable?
Typically, patents in Argentina are valid for 20 years from the filing date, subject to maintenance fees.
3. Are method claims in AR095554 enforceable in Argentina?
Yes, provided they meet patentability criteria and are sufficiently supported in the patent specification.
4. What are the prospects of patent extension or supplementary protection in Argentina?
Argentina does not offer supplementary protection certificates (SPCs) currently, limiting patent term extensions beyond 20 years.
5. How does patent AR095554 influence generic entry?
If the patent's claims are narrow, generic manufacturers may enter once the patent expires or is invalidated; broader claims can delay entry.
References
- Argentine Patent Office (INPI). (2022). Patent statistics and guidelines.
- World Intellectual Property Organization (WIPO). (2022). Patent landscape reports in Latin America.
- Marra, F., & Cruz, J. (2020). Patent strategies in Argentina’s pharmaceutical sector. Journal of Pharma Patent Law, 15(3), 22-34.
- Argentinian Law on Patents (Law 24477). (1996).
[1] Argentine Patent Office. (2022). Patent statistics report.
